The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Enzalutamide, docetaxel and androgen deprivation (ENZADA trial) for metastatic castrate sensitive prostate cancer (mCSPC).
 
Earle F Burgess
Stock and Other Ownership Interests - Arvinas; Becton Dickinson; Calithera Biosciences; Exelixis; Gilead Sciences; Macrogenics; Medtronic
Honoraria - Exelixis; Janssen Oncology; Merck; Novartis; Pfizer
Consulting or Advisory Role - Johnson & Johnson
Speakers' Bureau - AstraZeneca; Exelixis
Research Funding - Astellas Pharma; Pfizer
 
Claud Grigg
Consulting or Advisory Role - Bayer; EMD Serono; Exelixis; Exelixis; Pfizer/EMD Serono; Tempus
Research Funding - Tempus
Travel, Accommodations, Expenses - Calithera Biosciences; Pfizer
 
Danielle Boselli
No Relationships to Disclose
 
Sarah Norek
No Relationships to Disclose
 
Xhevahire J Begic
No Relationships to Disclose
 
David L. Graham
Speakers' Bureau - Biopep Solution
 
James Thomas Symanowski
Consulting or Advisory Role - Astellas Pharma; Camurus; CARsgen Therapeutics; Endocyte (Inst); Immatics; Lilly
Research Funding - Various (Inst)
 
Derek Raghavan
Consulting or Advisory Role - Caris Life Sciences (Inst)